Pfizer Property, Plant, and Equipment 2012-2026 | PFE
Pfizer property, plant, and equipment from 2012 to 2026. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
- Pfizer property, plant, and equipment for the quarter ending March 31, 2026 was $18.880B, a 1.83% increase year-over-year.
- Pfizer property, plant, and equipment for 2024 was $18.393B, a 2.89% decline from 2023.
- Pfizer property, plant, and equipment for 2023 was $18.94B, a 16.38% increase from 2022.
- Pfizer property, plant, and equipment for 2022 was $16.274B, a 9.35% increase from 2021.
|
Pfizer Annual Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2024 | $18,393 |
| 2023 | $18,940 |
| 2022 | $16,274 |
| 2021 | $14,882 |
| 2020 | $13,745 |
| 2019 | $12,969 |
| 2018 | $13,385 |
| 2017 | $13,865 |
| 2016 | $13,318 |
| 2015 | $13,766 |
| 2014 | $11,762 |
| 2013 | $12,397 |
| 2012 | $13,213 |
| 2011 | $15,921 |
|
Pfizer Quarterly Property, Plant, and Equipment (Millions of US $) |
|
|---|---|
| 2025-09-30 | $18,880 |
| 2025-06-30 | $18,776 |
| 2025-03-31 | $18,347 |
| 2024-12-31 | $18,393 |
| 2024-09-30 | $18,541 |
| 2024-06-30 | $18,957 |
| 2024-03-31 | $18,803 |
| 2023-12-31 | $18,940 |
| 2023-09-30 | $17,862 |
| 2023-06-30 | $17,488 |
| 2023-03-31 | $17,052 |
| 2022-12-31 | $16,274 |
| 2022-09-30 | $15,441 |
| 2022-06-30 | $15,244 |
| 2022-03-31 | $15,109 |
| 2021-12-31 | $14,882 |
| 2021-09-30 | $14,436 |
| 2021-06-30 | $14,224 |
| 2021-03-31 | $14,011 |
| 2020-12-31 | $13,745 |
| 2020-09-30 | $14,403 |
| 2020-06-30 | $14,113 |
| 2020-03-31 | $14,040 |
| 2019-12-31 | $12,969 |
| 2019-09-30 | $13,701 |
| 2019-06-30 | $13,521 |
| 2019-03-31 | $13,467 |
| 2018-12-31 | $13,385 |
| 2018-09-30 | $14,036 |
| 2018-06-30 | $13,919 |
| 2018-03-31 | $13,971 |
| 2017-12-31 | $13,865 |
| 2017-09-30 | $13,505 |
| 2017-06-30 | $13,386 |
| 2017-03-31 | $13,238 |
| 2016-12-31 | $13,318 |
| 2016-09-30 | $13,284 |
| 2016-06-30 | $13,609 |
| 2016-03-31 | $13,584 |
| 2015-12-31 | $13,766 |
| 2015-09-30 | $13,695 |
| 2015-06-30 | $11,432 |
| 2015-03-31 | $11,527 |
| 2014-12-31 | $11,762 |
| 2014-09-30 | $12,032 |
| 2014-06-30 | $12,179 |
| 2014-03-31 | $12,347 |
| 2013-12-31 | $12,397 |
| 2013-09-30 | $12,359 |
| 2013-06-30 | $12,443 |
| 2013-03-31 | $13,950 |
| 2012-12-31 | $13,213 |
| 2012-09-30 | $14,606 |
| 2012-06-30 | $14,756 |
| 2012-03-31 | $16,192 |
| 2011-12-31 | $15,921 |
| 2011-09-30 | $17,721 |
| 2011-06-30 | $18,281 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |